Demand For Somulin Soars On The Heels of FDA Prescription Sleep Product Report
In a recent effort to ensure consumer safety, the Food and Drug Administration (FDA) are urging manufacturers of prescription sleep aides to strengthen their manufacturers warning labels about potential harmful side effects. With the recent surge in death related incidences due to prescription sleep aides, other over-the-counter (OTC) medications, like Somulin, have seen a soar in sales by consumers looking for a natural, safer alternative to a good nights sleep.
In the last year, the FDA has requested more than 13 manufacturers of prescription sleep-aides, to provide in-depth clinical studies on the harmful side effects consumers could experience while take sleeping pills. Common, yet dangerous side effects consumers have reported were driving while sleeping, binge eating during the night, and other complex behavioral issues. These conditions may seem rare in comparison to other safety related issues, but with an increase of 60% in sleep medications in the last 5 years, the increase in incidence is causing the government and consumers to sit up and take notice.
Not all sleep aides are prescription, or considered harmful. The FDA has approved OTC medications for use up to two weeks for consumers who need temporary relief of sleepless nights. Products like Somulin provide a safe, two part system that contains Serotain™ and Velarian Root which enables your body to naturally relax and fall asleep, without harmful side effects. They are also non-habit forming which alleviates any complex sleep-related behaviors that are known to occur with sedative-hypnotic drugs that are taken long term.
For more information on safer sleeping, visit http://www.somulin.com/
- Contact Information
- Lizia Grinberg
- Public Relations
- Global Media Group
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.